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Abstract of Dissertation
Amalgamation of Nucleosides and Amino Acids in Antibiotic Biosynthesis

The rapid increase in antibiotic resistance demands the identification of novel
antibiotics with novel targets. One potential antibacterial target is the
biosynthesis of peptidoglycan cell wall, which is both ubiquitous and necessary
for bacterial survival. Both the caprazamycin-related compounds A-90289 and
muraminomicin, as well as the capuramycin-related compounds A-503083 and
A-102395 are potent inhibitors of the translocase I enzyme, one of the key
enzymes required for cell wall biosynthesis. The caprazamycin-related
compounds contain a core nonproteinogen β-hydroxy-α-amino acid referred to as
5’-C-glycyluridine (GlyU). Residing within the biosynthetic gene clusters of the
aforementioned compounds is a shared open reading frame which encodes a
putative serine hydroxymethyltransferase (SHMT). The revelation of this shared
open reading frame resulted in the proposal that this putative SHMT catalyzes
an aldol-type condensation reaction utilizing glycine and uridine-5’-aldehyde,
resulting in the GlyU core. The enzyme LipK involved in A-90289 biosynthesis
was used as a model to functionally assign this putative SHMT to reveal its
functions as an L-threonine: uridine-5’-aldehyde transaldolases. Biochemical
analysis indicates enzymatic activity is dependent upon pyridoxal-5’-phosphate,
is non-reactive with alternative amino acids, and produces acetaldehyde as a coproduct. Structural characterization of the enzymatic product is consistent with
(5’S,6’S)-GlyU indicating that this enzyme orchestrates a C-C bond breaking and
formation resulting in two new stereocenters to make a new L-α-amino acid. The
same activity was demonstrated for the LipK homologues involved in the
biosynthesis of muraminomicin, A-503083, and A-102395. This L-threonine:
uridine-5’-aldehyde transaldolase was used with alternative aldehyde substrates
to prepare unusual L-α-amino acids, suggesting the potential for exploiting this
enzyme to make new compounds.
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Chapter One
INTRODUCTION

1.1 Searching for new antibiotics
The drastic increase in antibacterial resistance requires priority be given to the
formation and discovery of novel antibacterial compounds. The limited shelf life
of antibiotics is due in part to the natural or acquired resistance mechanism of the
organism, which has been correlated to the quantity of antibiotic used, the
frequency of use, the size of the population it’s prescribed for, the resistance
mechanisms for the drug already present in the organism, the quantity of
mutations required for resistance in the organism, and the fitness of the resistant
organism. Currently, an innovation gap exists in finding novel antibacterial
structures that deviate from the main classes of antibiotics; the β-lactams, the
macrolides, sulfonamides, and the fluoroquinolones (Fig. 1.1), the majority of
which were discovered more than 60 years ago (1). Therefore, the search for
novel antibacterial compounds continues.

O
HO
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HO
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OH
O

R N S
O N
O
OH
O
β-lactam (penicillins)
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Fluoroquinolone

Figure 1.1 Structural examples of the main classes of antibiotics.
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Natural products have been one of the leading sources of unprecedented
bioactive compounds. Over the last 25 years, more than 60% of small-molecule
compounds introduced as novel drugs were derived from natural products (2).
However, as of late, pharmaceutical companies have focused on combinatorial
chemistry, high-throughput screening of synthetic chemical libraries, and
computer assisted design for novel drug compound development (3). While
methods of identifying novel drug compounds vary over time, the consistency of
natural products to unearth elaborate, novel compounds is still unequaled.
Displaying complex scaffolds with richly deployed functional groups, natural
products utilize enzymatic pathways which enable structural diversity that cannot
be synthesized and is essential in drug development (4). One potential strategy
to harness the unique capabilities of these unprecedented structures and
optimize current drug compounds, is using a biosynthetic approach for
production and discovery of these complex compounds.

1.1.1 Current antibacterial targets
Multiple sites in bacterial replication have proven effective targets for bacterial
growth inhibition. Protein biosynthesis, DNA and RNA replication, thymine
biosynthesis, cell surface decoration, isoprenoid biosynthesis, and peptidoglycan
cell wall formation have all proven effective antibacterial targets. Protein
biosynthesis targeting the bacterial ribosome within the organism is one primary
target for antibiotics. The bacterial ribosome consists of two subunits (30S and
50S) of rRNA and protein. Antibiotics such as macrolides and oxazolidones bind
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to the 50S unit while aminoglycosides and tetracyclines bind to the 30S unit
inhibiting protein biosysnthesis (5-7). These inhibitors thus derail essential
biosynthesis of proteins resulting in cell death.

DNA and RNA replication, as well as thymine biosynthesis are two more classical
antibacterial targets. The antibiotics rifampin, ciprofloxacin, and the novobiocins
successfully inhibit DNA and RNA formation during bacterial growth and
therefore prevent antibacterial replication. Rifampin functions by binding to RNA
polymerase and therefore inhibiting the polymerase from attaching to the DNA for
transcription. Ciprofloxacin and novobiocins repress the introduction of supercoils
in DNA by binding to DNA gyrase. By inhibiting DNA and RNA formation, the
ability of the organism to survive is greatly reduced (6, 8). Thymine, generated
by folate metabolism and utilized in DNA formation, is another successful target
for antibitiotics such as sulfamethoxazole and trimethoprim. By depleting
dihydropteroate, sulfamethoxazole inhibits dihydropteroate synthase by reducing
the amount of dihydrofolate and thus folate. Trimethoprim, another antibacterial
compound successful in inhibiting bacterial replication, inhibits the formation of
tetrahydrofolate. By depleting dihdrofolate reductase, the compound
trimethoprim successfully prohibits the formation of tetrahdyrofolate from
dihydrofolate and therefore halts folate synthesis (9, 10).
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Two more potential antibacterial targets are cell surface decoration and
isoprenoid biosynthesis. Sortases, present in gram-positive bacteria, are
enzymes which cleave cell surface proteins. These enzymes are anchored into
the membrane by membrane spanning sequences containing an amino terminal
and they covalently attach to the peptidoglycan cell wall by an amino terminal
cleavage fragment of the surface protein (11). Another unique target not present
in higher organisms is the non-classical (non-mevalonate) pathway of isoprenoid
biosynthesis. Isotopic labeling studies have shown a divergence in the formation
of isoprenoid units between most human pathogens and vertebrates.
Vertebrates utilize the mevalonate pathway while most human pathogens
incorporate isoprenoid units by means of the non-mevalonate pathway. This
alternative pathway utilizes enzymes such as 1-deoxy-D-xylulose 5-phosphate
reductoisomerase and 1-hydroxy-2-methyl-2-(E)-butenyl D-erythritol 2,4cyclodiphosphate synthase which would be ideal targets for antibacterial
compounds due to the lack of mammalian homologs (12, 13).

Finally, the peptidoglycan cell wall is a prime target due to its multiple inhibition
sites, its presence in both gram-positive and gram-negative bacteria, and its
necessity for the survival of nearly all bacteria. Peptidoglycan cell wall
biosynthesis requires multiple enzymes, many of which are ideal targets for
antibacterial inhibition. Peptidoglycan contains N-acetylglucosamine (glcNac)
and N-acetyl-muramic acid (MurNAc), two hexoses forming the backbone of a
cross-linked polymer. Lipids I and II are formed when the peptidoglycan units are
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transferred to a carrier lipid which transports the precursors across the cellular
membrane. One of the key enzymatic activities is that of transporting molecules
aided by the translocase enzymes (14).

1.1.2 Formation of the Peptidoglycan cell wall
The biosynthesis of peptidoglycan cell wall has proven a viable target for
antibacterial compounds. Drugs such as fosfomycin inhibiting MurA, ramoplanin
inhibiting MurG, vancomycin inhibiting transglycolastion, and the β-lactams which
inhibit the transpeptidation step have all been clinically used as antibiotics (1518). The peptidoglycan cell wall is assembled by a series of enzymatic reactions
within the cytoplasm as well as the periplasm that are depicted in Figure 1.2.
The initial steps in the biosynthetic pathway are composed of stepwise additions
of L-Ala, D-Glu, L-Lys or M-DAP, and D-Ala-D-Ala onto UDPMurNAc. This
sequence is catalyzed by a series of ATP-dependent ligases MurC-F to form the
precursor UDPMurNAc-pentapeptide. The pentapeptide then forms lipid I when
it is transferred onto a lipid carrier undecaprenyl phosphate catalyzed by the
enzyme bacterial translocase Ior MraY. Lipid II is subsequently formed when the
product of MraY is tailored by the addition of a GlcNAc sugar onto the 4′-hydroxyl
or MurNAc catalyzed by the enzyme MurG. The lipid-linked intermediate is then
transported across the cytoplasmic membrane to the periplasm. Lipid II then
undergoes transglycosylation to form a polysaccharide that is cross-linked by
transpeptidation. The transglycosylation releases the undecaprenyl
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pyrophosphate and then recycles it by means of dephosphorylation and “flipped”
back to the cytoplasm to serve as a substrate for MraY (13) (Fig. 1.2).

Figure 1.2 Step wise biosynthesis of the peptidoglycan cell wall within grampositive and gram-negative bacteria. This residue is either an L-lysine in grampositive bacteria or diaminopimelic acid in gram-negative bacteria.

1.2 Translocase I inhibitors

A key step in the biosynthesis of the peptidoglycan cell wall is the transfer of
phosphor-N-acetylmuramic acid pentapeptide from UDP-N-acetylmuramic acid
pentapeptide to undecaprenyl phosphate catalyzed by the enzyme MraY (Fig.
1.3)(19-21). The integral ten transmembrane, α-helical protein is ubiquitious
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within bacteria, and lacks any mammalian homolog thus making it an ideal target
for antibacterial compounds. However, while the identity of MraY was revealed
in 1993, lack of tertiary structure and the refractory nature to overexpression and
purification to homogeneity of this protein has rendered biochemical studies to be
very difficult (13, 22). Fortunately, a small amount of Bacillus subtilis MraY has
been purified to homogeneity and crude extracts of MraY from Escherichia coli
and Stapylococcus aureus, have been obtained. Comparative analysis of the
enzymes reveals five cytoplasmic and six perplasmic conserved domains.
Alignment of the MraY cytoplasmic domains from E. coli, B. subtilis, and S.
aureus maintain multiple highly conserved residues including three strictly
conserved aspartic acid residues (Asp-115, Asp-116, and Asp-267) which may
form the active site of the enzyme (23, 24).

Figure 1.3. Enzymatic activity of the translocase I enzyme MraY. The Mg2+
dependent reaction initiates the phosphor-transfer of UDP-N-acetylmuramic acid
to the isoprenoid unit embedded within the lipid wall subsequently forming UMP
and lipid I.
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Despite the difficulty associated with studying MraY, several screens over the
past decade have discovered several classes of natural product antibiotics which
have shown to inhibit MraY. Tunicamycins, mureidomycins, liposidomycin,
muraymycin, capuramycin, and caprzamycin are examples of the classes of
antibiotics which contain a uridine-like moiety with a high carbon furanoside (Fig.
1.4). Highlighted by a uridine disaccharide extended by a fatty acyl chain, the
tunicamycins consist of one family of reversible, competitive MraY inhibitors.
However, due to inhibition of GlcNAc-1-P transferase in glycoprotein
biosynthesis, tunicamycins are toxic to mammals (25).

Two distinct classes of uridine-containing MraY inhibitors are the peptidyl
nucleoside products mureidomycins and the liposidomycins. Mureidomycins
contain a 3ʹ′-deoxyuridine sugar moiety and are highlighted by a unique peptide
chain that is attached by means of an unusual enamide linkage. The peptide
chain includes an N-methyl 2,3-diaminobutyric acid reside as well as a urea
linked to a C-terminal aromatic amino acid of meta-tyrosine, Trp, or Phe. These
slow binding inhibitors are believed to act by binding to the Mg2+ cofactor-binding
site of MraY at the amino terminus (20). The liposidomycins consist of a sulfated
aminoglycoside and fatty-acyl residues bonded to the uridine-containing core.
These slow binding inhibitors show moderate activity against solubilized E. coli
MraY. However, synthetic analogs of these compounds appear more promising
due to better activity and increased spectrum of antibacterial activity (14, 19).

	
  

8

The muraymicyms represent another family of MraY inhibitors that contain an
aminoribofuranoside monosaccharide connected to a peptide chain, that has an
unusual urea linked to a C-terminal amino acid. These potent inhibitors show
promising antibacterial activity against drug-resistant strains of S. aureus and
Enterococci. Synthetic analogues of these compounds, which lack the
aminoribofuranoside, have reduced in vitro activity, but retain some antibacterial
activity (19, 26).

The final two classes, the caprazamycin and capuramycin-

related compounds, also inhibit the translocase I enzyme MraY and are the
classes focused on in this dissertation (21).
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1.2.1. Caprazamycin-related compounds
The liponucleoside antibiotics of the caprazamycin-related compounds show in
vitro activity against gram-positive bacteria with no significant toxicity unlike
tunicamycin, thus showing high potential as antibacterial compounds (27).
Discovered in 2003 by specific enzymatic screening for MraY translocase I
inhibition, the caprazamycin structure was established shortly thereafter in 2005
(28, 29). The core skeleton consists of an N-alkylated 5′-(β-O-aminoribosyl)glycyluridine which is shared with that of closely related liposidomycins also
shown to inhibit the formation of lipid I by inhibiting MraY translocase I (Fig. 1.5)
(13, 30).

A	
  

B	
  

Figure 1.5. Nucleosid antibiotics of the translocase I inhibitor family
highlighting the N-alkylated 5′-(β-O-aminoribosyl)-glycyluridine core. (A)
The caprazamycin family of the MraY translocase I inhibitor family. (B) The
liposidomycin family of the MraY translocase I inhibitor family.
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1.2.2 Capuramycin-Related Compounds
The capuramycin analogs, also containing a uridine core with a high carbon
furanose, show potent MraY translocase I inhibition with IC50 values within 10-20
nm. In contrast to the caprazamycin-related compounds, the capuramycinrelated compounds are highlighted by a 5ʹ′-C-carbamoyluridine (CarU) core with
an unusual unsaturated hexose attached via a glycosidic bond (19, 31). Initially
discovered in 1986 by generic antibacterial activity screens, the specific analogs
A-503083 and A-500359 were identified by specific enzymatic screens to identify
inhibitors of MraY translocase I (Fig. 1.6) (31-34).
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R1 = CH3, R2 = H
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R1 = R2 = H

A-503083 A

R1 = CH3, R2 = CONH2

A-503083 B

R1 = H, R2 = CONH2

A-503083 E

R1 = OCH3, R2 = CONH2

A-503083 F

R1 = OH, R2 = CONH2

Figure 1.6. Nucleoside antibiotics of the translocase I inhibitor family
highlighting the 5′-C-carbamoyluridine.

We are interested in delineating the biosynthesis of the caprazamycin-like
compounds A-90289 isolated from Streptomyces sp. SANK 60405, and
muraminomicin isolated from Streptosporangium amethystogenes SANK 60709,
as well capuramycin-like compounds A-503083 isolated from Streptomyces sp.
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SANK 62799, and A-102395 isolated from Amycolatopsis sp. SANK 60206 (Fig.
1.7). All four compounds were discovered using an assay for identification of
MraY activity in vitro and therefore are potential leads as antibiotics that target
peptidoglycan cell wall biosynthesis (31, 35-37).
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Figure 1.7. MraY translocase I inhibitor compounds discussed in this
dissertation.

Previous work in our lab and others has identified the biosynthetic gene clusters
for the lipopeptidyl nucleoside family including the compounds A-90289 (a
caprazamycin-related compound), caprazamycins, and muraymycins. Each of
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the compounds contains an aminoribosyl moiety attached by means of a 5ʹ′-Oglycosidic bond to a 5ʹ′-C-glycyluridine moiety. The putative open reading frames
(orfs) shared within these clusters include those encoding a nonheme, Fe(II)dependent dioxygenase (LipL), a putative nucleotidylyltransferase (LipM), a
glycosyltransferase (LipN), an aminotransferase (LipO), a uridine phosporylase
(LipP), and a serine hydroxymethyltransferase (LipK) hypothesized to form the
5ʹ′-C-glycyluridine (GlyU) core. Prior studies in our group have revealed LipL as a
nonheme, Fe(II)-dependent dioxygenase converting UMP to uridine-5ʹ′-aldehyde
(UA), LipO as an L-methionine:UA aminotransferase utilizing UA as a substrate,
LipP as a low specificity phosphorylase, LipM as a primary amine-requiring
nucleotidylyltransferase, and LipN as a 5-amino-5-deoxyribosyltransferase (Fig.
1.8) (38, 39). However, while five of the six shared genes have been shown to
form the aminoribosyl moiety of the final compound, the putative serine
hydroxymethyltransferase (SHMT) and its activity in forming the GlyU core was
still in question.
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Figure 1.8. Biosynthesis of the disaccharide-containing nucleoside core of
lipopeptidyl nucleoside antibiotics. Enzymes in blue have been functionally
assigned.

Comparative bioinformatic analysis of the genes required for the formation of the
caprazamycin-related compounds and the capuramycin-related compounds A503083 and A-102395 revealed all of the clusters contain the orfs encoding the
non-heme, Fe(II)-dependent α-ketoglutarate: UMP dioxygenase (LipL) as well as
the putative SHMT. Gene deletion of the orf encoding the putative SHMTs from
the biosynthetic gene clusters responsible for forming the caprazamycin-related
compounds caused a failure to synthesize the final compound. Recently our lab
has revealed the necessity of the putative SHMT within the biosynthetic pathway
of A-102395 by showing the abolishment of production upon gene inactivation
(27, 31, 35, 40). The lack of any detectable product formation without the
presence of the putative SHMT within the biosynthetic gene cluster indicates
necessity of the enzyme for biosynthesis. Also, the shared LipL homolog
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amongst the biosynthetic gene clusters suggests that the UA product formed by
LipL and its homologs is a shared intermediate and may be a precursor substrate
for the putative SHMTs. These similarities prompted us to investigate the
function of the putative SHMT and to define its role in the biosynthesis of the
caprazamycin and capuramycin-related compounds.

The canonical SHMT is known primarily for its function in DNA biosynthesis by
the inter-conversion of Ser and tetrahydrofolate (THF) to Gly and N5, N10methylene-THF. However, the compound N5, N10-methylene-THF is known to be
the donor of a single carbon group for use not only in thymidine biosynthesis, but
also can be oxidized by to form the methenyl incorporated into purine
biosynthesis, or be reduced to form the methyl group donated to sulfur during
methionine biosynthesis (41, 42).

The formation of the single carbon donor N5, N10-methylene-THF is primarily
dependent on the SHMT. The essential role of SHMT has spawned numerous
reports describing the biochemistry, structure, and mechanism of this enzyme.
Under the umbrella of the B6-dependent (or PLP) enzymes, the SHMT is
classified as a member of the type I fold, or α-family. This particular enzyme
initiates a reaction by formation of an internal aldimine by binding a key Lys
residue with the co-factor pyridoxal-5ʹ′-phosphate (PLP) which enables Ser to
bind to PLP forming an external aldimine. The β-hydroxyl group is then
deprotonated by a general base of the enzyme initiating an electron
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rearrangement utilizing the PLP as an electron sink and forming formaldehyde
and a Gly bound PLP product. The formaldehyde group is then incorporated
onto THF in a series of reactions forming N5, N10-methylene-THF (Fig. 1.9) (4,
43).

While the in vivo role of canonical SHMTs in transferring the Cβ of Ser to THF is
well established, several studies have revealed that these SHMTs are also able
to catalyze numerous reactions in the absence of THF. Decarboxylation,
transamination, retroaldol cleavage, and racemization reactions have all been
seen at rates sometimes approaching or even surpassing those of physiological
reactions when THF is absent (44, 45). These in vitro studies of SHMTs raise
interesting questions about the role that the putative SHMTs play in the
biosynthesis of MraY inhibitors.

Another enzyme of great interest due to its similarity to the canonical SHMT is Lthreonine aldolase (LTA or LTAE). Also a type I fold PLP dependent enzyme,
the canonical LTA catalyzes the interconversion of L-Thr to Gly and
acetaldehyde. SHMT and LTA share similar catalytic properties and are able to
catalyze similar reactions including the retroaldol cleavage of varying L-3hydroxyamino acids, the transamination and the racemization of D- and L-alanine,
and the exchange of the α-proton of Gly with solvent. While both enzymes show
similar enzymatic activity, LTA and SHMT appear to have modest specificity for
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the retroaldol cleavage of L-allo-threonine and the Cβ of serine to H4PteGlu
respectively (4, 46).

Due to the intriguing chemistry catalyzed by SHMTs and LTAEs, including the
alternative reactions observed, we set out to establish the putative SHMTs
function within the biosynthetic gene clusters of the caprazamycin and
capuramycin-related compounds. We envisioned that the results would not only
provide a definitive biosynthetic pathway of the known MraY inhibitor
compounds, but also serve as a genetic fingerprint for identifying future
antibiotics.
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Figure 1.9. Reaction mechanism of the canonical SHMT utilizing Ser and
THF as substrates in the transfer of a single carbon unit.

	
  

NH2
NH

N

H
N

O

N

1.3. Aims of this study

The overarching objective of this study is to identify the enzymatic activity of the
putative SHMT shared among the A-90289, muraminomicin, A-102395, and A503083 biosynthetic gene clusters of the caprazamycin and capuramycin- related
compounds. We hypothesize d that these SHMT-like enzymes catalyze a PLP
dependent aldol-like condensation reaction incorporating the amino acid Gly onto
the known intermediate UA. This C-C bond formation would enable the
elongation of the furanoside and formation of the intermediate GlyU.

To interrogate this hypothesis, three specific aims were developed.
Aim I: Isolation and purification of SHMT. This objective was achieved by
cloning of the gene, confirming the identity by sequencing, obtaining soluble
protein from a heterologous host, and optimizing the purification process.

Aim II: Functional characterization of the putative SHMT. Characterization of the
putative SHMT would lead to identification of the enzymatic role played in the
biosynthesis of the final compounds. This role can also reveal novel chemistry
associated with C-C bond formation necessary in more complex antibacterial
compounds. This objective was achieved by identifying required co-factors,
determining viable substrates, identification of the putative SHMT product, and
optimization of reaction conditions for kinetic analysis of the enzymatic activity.
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Aim III: Verification of the expected activity of the putative SHMT in vivo. Due to
the novel chemistry associated with the putative SHMT and its preferred
substrates, identification of specific amino acids in vivo verifies the enzymatic
activity and necessity in C-C bond formation and the development of the high
carbon furanoside in caprazamycin and capuramycin-related antibacterial
biosynthesis. This task was accomplished by feeding isotopically enriched Gly
and L-Thr precursosrs to the producing strain of A-503083 and identifying
incorporation into the CarU core.

The canonical SHMT and LTA were used to compare with the newly
characterized putative SHMT from the caprazamycin and capuramycin-related
biosynthetic gene clusters. The results described here reveal new mechanistic
information for all three groups of enzyme catalysts.
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Chapter Two
Materials and Methods

2.1 Chemicals.
L-Thr [(2S,3R)-2-amino-3-hydroxybutyric acid], D-Thr [(2R,3S)-2-amino-3hydroxybutyric acid], L-allo-Thr [(2S,3S)-2-amino-3-hydroxybutyric acid],DL-alloThr,N-methyl-L-Thr, O-phospho-L-Thr, proteinogenic amino acids, uridine-5'monophoshate (UMP), uridine, α-ketoglutartate (αKG),β-nicotinamide adenine
dinucleotide (β-NAD+), potassium-activated aldehyde dehydrogenase (ADH) from
baker’s yeast, 2,4-dinitrophenylhydrazone (DPNH), tetrahydrofolic acid (THF),
pyridoxal-5’-phosphate (PLP), various aldehyde substrates, and buffers were
purchased from Sigma. Synthetic oligonucleotides were purchased from
Integrated DNA Technologies. DNA sequencing was performed using the
BigDye™Terminator version 3.1 Cycle Sequencing kit from Applied Biosystems,
Inc. (Foster City, CA) and analyzed at the University of Kentucky Advanced
Genetic Technologies Center.

2.2 Instrumentation.
UV/Vis spectroscopy was performed with a Bio-Tek µQuant microplate reader
using Microtest™ 96-well plates (BD Biosciences) or a Shimadzu UV/Vis-1800
Spectrophotometer equipped with a TCC-240A thermoelectrically temperature
controlled cell holder. PCR was performed with a Veriti® 96-well thermal cycler
	
  

20

from Applied Biosystems. Analytic HPLC was performed with one of three
systems: an Agilent 1200 Series Quaternary LC system equipped with a diode
array detector and an Eclipse XDB-C18 column (250mm x 4.6 mm, 5 µm), a
Dionex Ultimate 3000 Focused separation module (Bannockburn, IL) equipped
with a DAD-3000 (RS) and MWD-3000 (RS) diode array detector and an Acclaim
120 C-18 column (4.6 mm x 100 mm, 3 µm), or a Waters Alliance 2695
separation module (Milford, MA) equipped with a Waters 2998 diode array
detector and an analytical Apollo C-18 column (250 mm x 4.6 mm, 5 µm)
purchased from Grace (Deerfield, IL).

Semipreparative HPLC was performed with a Waters 600 controller and pump
(Milford, MA) equipped with a 996 diode array detector, 717plus autosampler,
and an Apollo C-18 column (250 mm x 10 mm, 5 mm) purchased from Grace
(Deerfield, IL). LC-electrospray ionization (ESI)-mass spectroscopy (MS) was
performed using an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent
Technologies, Santa Clara, CA) equipped with an Agilent 1200 Series
Quaternary LC system and an Eclipse XDB-C18 column (150mm x 4.6 mm, 5
mm, 80Å).High resolution (HR)-MS was performed at the Department of
Chemistry Mass Spectrometry Service Laboratory, University of Minnesota, using
a Bruker BioTOF II. NMR data were collected using a Varian Unity Inova 400 or
500 MHz spectrometer (Varian, Inc., Palo Alto, CA) or a Bruker AVANCE 500
MHz spectrometer (Bruker Biospin Corporation, Billerica, MA).
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2.3 Enzymes, strains, and growth media.
Escherichia coli JM109 was purchased from Takara Bio Inc. (Shiga, Japan).
Restriction enzymes and DNA modifying enzymes were purchased from Takara
Bio Inc. or New England BioLabs Inc. (Ipswich, MA). Proteases and nucleases
for genomic DNA preparation were purchased from Sigma-Aldrich. Media, growth
conditions, genomic DNA isolation, and recombinant DNA techniques for E. coli
(31) and actinomycetes (32) were performed as described. Streptomyces
avermitilis ATCC 31267 and Streptomyces coelicolor A3(2) ATCC BAA-471 were
obtained from the American Type Culture Collection (ATCC). Streptomyces
griseus IFO13350 was obtained from the Institute of Fermentation, Osaka (IFO).
Saccharopolyspora erythraea NRRL 3887 and Streptomyces sp. NRRL 30471
were obtained from the Agricultural Research Service Culture Collection (NRRL).
Streptomyces lividans TK21 was a gift from the John Innes Centre. Streptomyces
albus was a gift from Prof. José A. Salas, Universidad de Oviedo. The remaining
strains are part of the culture collection maintained at Daiichi-Sankyo Co., Ltd.

A-503083 B and A-503083 F were isolated from Streptomyces sp. SANK 62799
and purified as previously reported (31). Muraminomicin F was isolated as
previously described (47). MS and 1H-and 13C-NMR spectra (Fig. 2.1) were
consistent with this report.
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Figure 2.1. 1H-and 13C-NMR spectra of muraminomicin F.
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2.4 Synthesis of 5'-C-glycyluridinediastereomers.
The synthesis of (5S,6S)-5'-C-glycyluridine, (5R,6S)-5'-C-glycyluridine, and
(5S,6R)-5'-C-glycyluridine is reported in detail elsewhere (36). ESI-MS analysis
of (5S,6S)-5'-C-glycyluridineyieldedan [M+Na]+ion of m/z = 340.1, consistent with
the expected molecular formula of C11H15N3O8Na . NMR spectroscopic
analysis was obtained at neutral pH (zwitterionic form). 1H-NMR(600 MHz, D2O,
35 °C): δ = 4.30 (d, J = 3.1 Hz, 1 H, 6'-H), 4.40 (dd, J = 5.7 Hz, J = 1.5 Hz, 1 H,
4'-H), 4.45 (dd, J = 5.7 Hz, J = 5.3 Hz, 1 H, 3'-H), 4.48 (dd, J = 5.3 Hz, J = 3.7
Hz, 1 H, 2'-H), 4.64 (dd, J = 3.1 Hz, J = 1.5 Hz, 1 H, 5'-H), 6.00 (d, J = 8.2 Hz, 1
H, 5-H), 6.05 (d, J = 3.7 Hz, 1 H, 1'-H), 8.16 (d, J = 8.2 Hz, 1 H, 6-H). 13CNMR(126 MHz, D2O, 35 °C): δ = 60.04 (C-6'), 69.36 (C-5'), 72.85 (C-3'), 75.85
(C-2'), 87.57 (C-4'), 92.43 (C-1'), 104.81 (C-5), 144.47 (C-6), 154.09 (C-2),
168.59 (C-4), 173.35 (C-7')

2.5 Cloning of genes for heterologous expression.
Genes were amplified by PCR using Expand Long Template PCR System from
Roche (Indianapolis, IN) with supplied Buffer 2, 200 mM dNTPs, 5% DMSO, 10
ng DNA template, 5 U DNA polymerase, and 200 nM each of the following primer
pairs: EcglyA (forward) 5'GGTATTGAGGGTCGCATGTTAAAGCGTGAAATGAACATTG-3'/ (reverse) 5'AGAGGAGAGTTAGAGCCTTATGCGTAAACCGGGTAACG -3'; EcLTA (forward)
5'-GGTATTGAGGGTCGCATGTCCGTGCTGGGGCGG-3'/ (reverse) 5'-
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AGAGGAGAGTTAGAGCCTTAACGCGCCAGGAATGCAC-3'; lipK (forward) 5'GGTATTGAGGGTCGCATGACGGTGGGGGCTGGTG-3'/ (reverse) 5'AGAGGAGAGTTAGAGCCTCACAGCCCGGCCTCCACTT-3'; orf25 (forward) 5'GGTATTGAGGGTCGCATGACTGACACTAACGAGTTACGG -3'/ (reverse) 5'AGAGGAGAGTTAGAGCCTCATGGGTAATCGACGAAGTGGAA -3'; capH
(forward) 5'-GGTATTGAGGGTCGCATGACTGATATCAGGGAGCTCCGCAAG3'/ (reverse) 5'AGAGGAGAGTTAGAGCCTCAGGAGAACTCGACGAAATAGAAGGGAG-3'; and
Mra14 (forward) 5'GGTATTGAGGGTCGCAGCTAGTGGCAAGACATCTTTGGGCG-3'/ (reverse) 5'AGAGGAGAGTTAGAGCCTTGTAGAAGTCGGAACCCAGTGGCAGTG-3'. DNA
templates for PCR cloning were E. coli DH5α genomic DNA for EcglyA and
EcLTA, cosmid pN1 for lipK (48), cosmid pNCap02 for orf25, cosmid pMra02 for
Mra14, and cosmid N-4 for capH (49). The PCR program included an initial hold
at 94 °C for 2 min, followed by 30 cycles of 94 °C for 10 s, 56 °C for 15 s, and 68
°C for 60s per kb DNA. The gel-purified PCR product was inserted into pET-30
Xa/LIC using ligation-independent cloning as described in the provided protocol
to yield pET30-EcglycA, pET30-EcLTA, pET30-lipK, pET30-orf25, pET30-mra14,
and pET30-capH. The genes were sequenced to confirm PCR fidelity.
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2.6 Site-directed mutagenesis.
A K235A point mutation of LipK was generated by PCR amplification using
pET30-lipK as a template and the Expand Long Template PCR system
(RocheAppliedScience). Reactions were performed using the manufacturer's
provided Buffer 2 with 5% DMSO, primers of 5'CTTCGGCGGATCGACTCACGCGTCCTTCCCCGGGCCCC-3' and the reverse
complement (the engineered Ala codon is underlined), and a PCR program
consisting of an initial hold at 94°C for 2 min followed by 20 cycles of 94°C for
10s, 56°C for 20s, and 68°C for 7min. The template DNA was digested with 10
units of DpnI (NewEngland Biolabs) for 1h at 37°C and transformed into E.coli
NovaBlue competent cells. The introduction of the correct point mutation and the
sequence of the entire gene including 200bp upstream and downstream were
confirmed by DNA sequencing to yield pET30-lipK (K235A).

2.7 Heterologous production of proteins in E. coli.
Plasmids pET30-EcglycA and pET30-Eclta, were introduced into E. coli
BL21(DE3) cells, and the transformed strains were grown in LB supplemented
with 30 mg/mL kanamycin. Following inoculation of 500 mL of LB with 30 mg/mL
kanamycin, the cultures were grown at 18 °C until the cell density reached an
OD600~ 0.5 when expression was induced with 0.1 mM IPTG. Cells were
harvested after an overnight incubation at 18 °C and lysed in 100 mM Tris-HCl
(pH 8) and 300 mM KCl using a French Press with one pass at 15000 psi.
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Following centrifugation the protein was purified using affinity chromatography
with Ni-NTA agarose from Qiagen (Valencia, CA), and the recombinant proteins
were desalted into 50 mM phosphate (pH 7.5)(for EcGlyA and EcLTA), 100 mM
KCl, and 5 % glycerol using a PD-10 desalting column (GE Healthcare). The
purified protein was concentrated using an Amicon Ultra 10000 MWCO
centrifugal filter (Millipore) and stored as glycerol stocks (40%) at -20 °C. Protein
purity was assessed by 12% acrylamide SDS-PAGE; His6-tagged proteins were
utilized without further modifications. Protein concentration was determined using
Bradford protein assay or extension coefficients calculated using the ProtParam
tool available from ExPASY (LipK, ε280= 28,880 M-1cm-1; CapH, ε280= 30,940
M-1cm-1; EcGlyA, ε280= 46,300 M-1cm-1; EcLTA, ε280= 36,900 M-1 cm-1.

2.8 Subcloning and expression in Streptomyces lividans TK-64 or
Streptomyces albus.
Plasmids pET30-lipK, pET30-lipK(K235A), pET30-orf25, and pET30-mra14 were
digested with NdeI-HindIII and the DNA fragment of the expected size was
purified and ligated to the identical sites of pUWL201pw to yield pUWL201pwlipK, pUWL201pw-lipK(K235A), pUWL201pw-capH, pUWL201pw-orf25, and
pUWL201pw-mra14 respectively. The resulting plasmids were transformed into
S. lividans TK-64 using PEG-mediated protoplast transformation and plated on
M2CaO or R2YE. After 14 h at 28 °C, the plates were overlaid with 1 mL of water
supplemented with 200 mg of thiostrepton. Single colonies were transferred to
fresh M2CaO or R2YE plates supplemented with 10 mg/mL thiostrepton, and
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after 4 days at 28 °C positive transformants were confirmed by colony PCR using
InstaGene Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC
buffer II from Takara Bio Inc. (Shiga, Japan).

The recombinant strain was utilized to inoculate 50 mL R2YE containing 10
µg/mL thiostrepton, grown for 2 days at 28 °C at 250 rpm, and 2 mL transferred
to fresh 100 mL containing 10 µg/mL thiostrepton. Following growth for 3 days at
28 °C at 250 rpm, the cells from 400 mL of culture were collected by
centrifugation and washed with 60 mL of 100 mM potassium phosphate (pH 7.4),
300 mM KCl, and 1 mM PMSF and stored on ice for 10 min. Following
centrifugation at 4,000 rpm for 15 min at 4oC,the pellet was thoroughly
resuspended in 60 mL ice-cold 100 mM potassium phosphate (pH 7.4), 300 mM
KCl, and 1 mM PMSF and ~25 mg of lysozyme was subsequently added to the
suspension. After incubation on ice for 30 minutes, the suspension was mixed by
pipeting and subjected to one pass through a French press at 18,000 psi. The
cell debris was removed by centrifugation (17,500 rpm for 45 min), the cell-free
extract filtered using a 0.45 mm PVDF syringe filter, and the clarified extract was
loaded onto a gravity column containing 0.5 mL Ni-NTA resin that was preequilibrated with 100 mM potassium phosphate (pH 7.4) containing 300mM KCl.
The resin was washed with 10 volumes 100 mM potassium phosphate (pH 7.4)
containing 300 mM KCl followed by 10 volumes of 100 mM potassium phosphate
(pH 7.4) containing 300 mM KCl and 20 mM imidazole. The His6-tagged protein
was eluted with 10 volumes of 100 mM potassium phosphate (pH 7.4) containing
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300 mM KCl and 250 mM imidazole and concentrated to < 2.5 mL using an
Amicon Ultra 10k MWCO. The sample was desalted into 35 mM potassium
phosphate (pH 7.4) containing 100 mM KCl using a gravity flow PD-10 column
following the manufacturer’s instructions. The purified protein was reconcentrated and stored as a 40% glycerol stock at -20°C.

2.9 Subcloning and expression of CapH into S. lividans TK-64.
Plasmid pET30-CapH was digested with NdeI-HindIII and the DNA fragment of
the expected size was purified and ligated to the identical sites of pUWL201pw to
yield pUWL201pw-CapH. The resulting plasmids was transformed into S. lividans
TK-64 using PEG-mediated protoplast transformation and plated on M2CaO agar
plates. After 16 hr at 28 °C, the plates were overlaid with 1 mL of nutrient agar
supplemented with 200 mg of thiostrepton. Single colonies were transferred to
fresh M2CaO plates supplemented with 25mg/mL thiostrepton, and after 4 days
at 28 °C positive transformants were confirmed by colony PCR using InstaGene
Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer II
from Takara Bio Inc. (Shiga, Japan).

The recombinant strain was utilized to inoculate 50 mL M2CaO containing 10
mg/mL thiostrepton, grown for 2 days at 28 °C at 250 rpm, and 2 mL transferred
to fresh 100 mL containing 10 mg/mL thiostrepton. Following growth for 3 days at
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28 °C at 250 rpm, the cells from 1000 mL of culture were collected by
centrifugation at 4,000 rpm for 15 min at 4oC, the pellet was thoroughly resuspended in ice-cold and re-suspended with 250 mL of 100 mM potassium
phosphate pH 7.4, 300 mM KCl and stored on ice. After incubation on ice for 30
minutes, the cell suspension was mixed by pipeting and subjected to one pass
through a French press at 18,000 psi. The cell debris was removed by
centrifugation (17,500 rpm for 45 min), the cell-free extract filtered using a 0.45
mm PVDF syringe filter, and the clarified extract was loaded onto a gravity
column containing 0.5 mL Ni-NTA resin that was pre-equilibrated with 100 mM
potassium phosphate containing 300 mM KCl. The resin was washed with 10
volumes 100 mM potassium phosphate pH 7.4 containing 300 mM KCl (Buffer A)
followed by 10 volumes of Buffer A containing 20 mM imidazole. The His-tagged
protein was eluted with 10 volumes of Buffer A containing 250 mM imidazole and
concentrated to < 2.5 mL using an Amicon Ultra 10k MWCO. The sample was
desalted into 35 mM potassium phosphate pH 7.4 containing 100 mM KCl using
a gravity flow PD-10 column following the manufacturer’s instructions. The
purified protein was re-concentrated and stored as a 40% glycerol stock at -20
o

C.

2.10 HPLC analysis of the reactions catalyzed by LipK, CapH, Orf 25, and
Mra14. Routine reactions for LipK, CapH, Orf25, and Mra14 consisted of 50 mM
HEPES or TES (pH 7.5), 2 mM UA, 5 mM co-substrate, 0.1 mM PLP, and 3.5
mM LipK at 30 °Cat the indicated time points. Following removal of the protein by
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ultrafiltration or TCA precipitation (7%), the reaction components were analyzed
using reverse-phase chromatography using the Agilent 1200 series HPLC
equipped with an Eclipse XDB-C18 column or a Dionex Ultimate 3000 Focused
separation module (Bannockburn, IL) equipped with a DAD-3000(RS) and MWD3000(RS) diode array detector and an Acclaim 120 C-18 column (4.6 mm x 100
mm, 3 mm). A series of linear gradients was developed from 0.1 % TFA in 0.5 %
acetonitrile (A) to 0.1% TFA in 90% acetonitrile (B) in the following manner
(beginning time and ending time with linear increase to % B): 0-8 min, 100% B;
8-28 min, 100% B; 28-32 min, 100% B; and 32-35 min, 0% B. The flow rate was
kept constant at 1 mL/min, and elution was monitored at 260 nm.

2.11 Isolation of the LipK product.
A large scale reaction (33 mL) consisted of 50 mM TES (pH 7.5), 100 mM KCl,
0.1 mM PLP, 1 mM DTT, 10 mM L-Thr, 2.5 mM uridine-5’-aldehyde, 3 mM NAD,
10 U ADH, and 5 mM LipK. Following incubation for 24 h at 30 °C, protein was
removed by ultra filtration and the product was partially purified by HPLC using a
C-18 reverse-phase semi-preparative column. A series of linear gradients was
developed from A to B in the following manner (beginning time and ending time
with linear increase to % B): 0-4 min, 100% B; 4-24 min, 50% B; 24-26 min,
100% B; 26-32 min, 100% B; and 32-35 min, 0% B. The flow rate was kept
constant at 3.5 mL/min, and elution was monitored at 260 nm. Fractions
containing the desired product eluting near the column void volume were
combined and lyophilized to yield a viscous, clear solution. The amount of
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product was estimated using 262 nm = 10,100 M-1 (50). Partially purified GlyU
was resuspended in 5 mL of 200 mM ammonium acetate (pH 8.8) and loaded
onto a column containing 1 mL of immobilized boronic acid resin (Thermo-Fisher)
that was equilibrated in 10 mL of 200 mM ammonium acetate (pH 8.8). Following
a 3 mL wash with the same buffer, the bound GlyU was eluted with 12 mL of 0.1
M formic acid. The purified sample was lyophilized prior to spectroscopic
analysis.

2.12 Phosgene modification of GlyU.
Phosgene modification of β-hydroxy-α-amino acids was carried out as previously
described (51). Approximately 20 mg of partially purified GlyU was dissolved in 1
M potassium hydroxide (6.5 mL), and the solution cooled to 5°C prior to the
addition of 6 mL of a 20% solution of phosgene in toluene. Following 5 min with
rigorous stirring, the mixture was acidified with 10 drops of concentrated HCl, and
the aqueous phase was removed and subjected to HPLC for purification using a
C-18 reverse-phase semi-preparative column following the above conditions. The
purified product was lyophilized and subjected to spectroscopic analysis. 1HNMR (D2O, 500 MHz): δ7.56 (d, J= 8.5 Hz, 1H), 5.95 (d, J= 5.0 Hz, 1H), 5.90 (d,
J= 8.0 Hz, 1H), 5.08 (dd, J= 5.0 Hz,J= 2.5 Hz,1H),4.55 (d, J= 5.5Hz, 1H), 4.45 (t,
J= 5.25Hz, 1H),4.41 (t, J= 5.0Hz, 1H), 4.30 (dd, J= 5.25Hz, J= 2.5 Hz,1H). 13CNMR (D2O, 100 MHz): δ 173.54, 165.85, 159.98, 151.51, 141.03, 102.60, 89.09,
83.33, 77.59, 72.71, 69.24, 62.38, 55.83.
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For analytical analysis of synthetic GlyU diastereomers, a 2 mM solution (50 mL)
of pure diastereomer was prepared and chilled on ice for 5 min. After addition of
10 mL of 5 M KOH, the reaction was initiated by adding 50 mL of 20% phosgene
in toluene. After a 1 h incubation on ice with periodic mixing, the organic phase
was removed and the aqueous phase analyzed by HPLC using the Agilent 1200
series HPLC Agilent 1200 Series equipped with an Eclipse XDB-C18 column and
gradient conditions described above for isolation of the LipK product.

2.13 Modification of aldehydes with DPNH.
LipK reaction components were modified with DPNH as previously described
(52). Following protein removal by centrifugation, the modified components were
analyzed using reverse-phase chromatography using the Agilent 1200 series
HPLC Agilent 1200 Series equipped with an Eclipse XDB-C18 column. A series
of linear gradients was developed from A to B in the following manner (beginning
time and ending time with linear increase to % B): 0-8 min, 100% B; 8-28 min,
100% B; 28-32 min, 100% B; and 32-35 min, 0% B. The flow rate was kept
constant at 1 mL/min, and elution was monitored at 430 nm.

2.14 Kinetic analysis of LipK and CapH.
Single-substrate kinetic analysis was carried out by monitoring the reduction of βNAD+ using ε340= 6220 M-1cm-1. Reaction mixtures (90 mL) consisting of 100
mM TES (pH 7.5), 100 mM KCl, 1 mM DTT, 30 mM L-Thr, 0.1 mM PLP, 2 mM β	
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NAD, and variable UA (1.0-125 mM) were incubated at 30 oC for 1 min prior to
initiation with a mixture (10 mL) consisting of 50 mM TES (pH 7.5), 100 mM KCl,
1 mM DTT, 2 mM β-NAD, 1 U ADH, and 250 nM LipK or CapH. Reactions were
carried out for 10 min, and rates were calculated using linear regression analysis
with data obtained under initial velocity conditions (< 10% product). Data were
fitted to the Michaelis-Menten equation using GraphPad Prism 5.0.4 (GraphPad
Software, Inc., La Jolla, CA). Each data point represents the average of a
minimum of three independent measurements.

Bi-substrate kinetic analysis for LipK were performed using reactions as
described above with variable UA (1.0 -60 mM) and L-Thr (62 mM –15.6 mM).
For mechanistic determination (ping pong versus sequential mechanism) the
inverse data (1/[S] versus1/v) were analyzed by simple linear regression
analysis. If data are fitted to an equation (Fig. 2.2; (53)) describing a random
sequential mechanism as described for serine hydroxymethyltransferases (54),
the global fit yields a kinetic constant of Km= 31 mM with respect to L-Thr and α=
0.88 (α is the factor by which the binding of one substrate alters the dissociation
constant for the remaining substrate; an αvalue of unity indicates substrate
binding has no effect on the binding of the respective substrate).

1 ∝ 𝐾!
𝐾! 1
1
∝ 𝐾!
=
1+
+
1+
𝑣 𝑉!"#
[𝐴] [𝐵] 𝑉!"#
[𝐴]
Figure 2.2 Equation for simple linear regression analysis.
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2.15 Isotopic Enrichment.
Fermentation media and growth conditions for Streptomyces sp. SANK 62799
were as previously described (31). A seed culture was incubated at 28 oC for 48
h when 1.5 mL was used to inoculate fresh media (50 mL liquid medium in a 250
mL flask). After fermentation for 70 h, 25 mg of filter-sterilized [1-13C]Gly, [213

C]Gly, or L-[13C4,15N]Thr was added to each flask. Fermentation was continued

an additional 72 h. An equal volume of methanol was added directly to the
culture and mixed vigorously prior to centrifugation to remove cell debris. The
supernatant was lyophilized and the dried powder was resuspended in water
(100 mg/mL) for HPLC analysis using a C-18 reverse-phase semi-preparative
column. A series of linear gradients was developed from A to B in the following
manner (beginning time and ending time with linear increase to % B): 0-6 min,
0% B; 6-26 min, 100% B; 26-30min, 100% B; 30-34 min, 0% B; and 34-35 min,
0% B. The flow rate was kept constant at 3.5 mL/min, and elution was monitored
at 260 nm. Relative peak intensities were assigned based on the relative
intensity of C -2''and C-3'' from the natural abundance spectrum.

2.16 HPLC analysis of the reactions catalyzed by EcGlyA and EcLTA with
2-pyridinde-carboxaldehyde and L-Thr.
Routine reactions EcGlyA and EcLTA consisted of 50 mM potassium phosphate
(pH 7.5), 2 mM 2-pyridine-carboxaldehyde, 5 mM L-Thr, 0.1 mM PLP, and 5.0
mM EcGlyA or EcLTA at 30 °C for the indicated time points. Following removal of
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the protein by ultrafiltration, the reaction components were analyzed using
reverse-phase chromatography using the Dionex Ultimate 3000 Focused
separation module (Bannockburn, IL) equipped with a DAD-3000(RS) and MWD3000(RS) diode array detector and an Acclaim 120 C-18 column (4.6 mm x 100
mm, 3 mm). A series of linear gradients was developed from 0.1 % TFA in 0.5 %
acetonitrile (A) to 0.1% TFA in 90% acetonitrile (B) in the following manner
(beginning time and ending time with linear increase to % B): 0-8 min, 100% B;
8-28 min, 100% B; 28-32 min, 100% B; and 32-35 min, 0% B. The flow rate was
kept constant at 1 mL/min, and elution was monitored at 260 nm.
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Chapter Three
RESULTS and Discussion

3.1. Heterologous expression of putative serine hydroxymethyltransferases
(SHMT)

The uniqueness of the C-C bond formation involved in SHMT activity and the
presence of a single putative SHMT within the biosynthetic gene clusters of the
caprazamycin and capuramycin-related compounds under investigation
prompted inquiry into the function of these putative enzymes. However, initial
investigation of the putative SHMTs required the isolation of the initial DNA,
insertion into the selected vector system, and expression of a soluble protein.

3.1.1 Isolation of the putative SHMTs from cosmid DNA
Bioinformatic analysis of each of the biosynthetic gene clusters of
muraminomicin, A-90289, A-503083, and A-102395 previously revealed the
presence of a putative SHMT within each cluster. The moderate sequence
similarity/identity of the putative SHMTs to each suggested a shared function of
each enzyme in the biosynthesis of the final compounds (Table 3.1). In order to
elucidate the function of the putative SHMTs and their mechanism in the
biosynthesis of the caprazamycin-related and capuramycin-related compounds,
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we cloned and expressed the genes from cosmid DNA generously provided by
Daiichi Sankyo Novare.

Primers for amplification of the putative SHMTs for the caprazamycin-related
compounds muraminomicin and A-90289 were designed from the sequence, and
the genes of interest were then amplified by PCR from the cosmid DNA pMra02
and pLip02 respectively. The putative SHMTs for the capuramycin-related
compounds A-503083 and A-102395 were amplified form the cosmid DNA N-1
and NCap02 respectively. After agarose gel purification, the DNA was then
inserted into the pET30 Xa/LIC vector and sequentially transformed into
NovaBlue cells purchased from Novagen. Individual colonies were then selected
and grown in a 3.0 mL LB culture containing the antibiotic selection marker
kanamycin. The cells were collected and the plasmid was purified. The gene of
the purified plasmid was sequenced to ensure 100% identity to the expected
sequence.

Table 3.1. Putative SHMT DNA comparison. Comparison of the DNA
sequence of the individual putative SHMTs. %Identical/%Similar.
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orf25	
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3.1.2 Protein expression of putative SHMTs
After sequencing to confirm the identity, the plasmids encoding the putative
SHMTs were tested for their ability to produce soluble, recombinant protein. Cell
lines for pET30-lipK, pET30- capH, pET30-mra14, and pET30-orf25 were
created by transformation of each respective vector into E. coli BL21(DE3) cells.
The cells were then plated and cultured in LB broth with the antibiotic selection
marker kanamycin. A one-liter culture was grown for each of the above cell lines
and gene expression induced with IPTG. Unfortunately none of the above
proteins were soluble in the E. coli strain, therefore an alternative expression
system was chosen. The pET30 Xa/LIC vectors containing the cloned genes
were digested with the restriction enzymes NdeI and HindIII to remove the
putative SHMT genes including the engineered sequence for an N-terminal His6tag. The DNA fragment was then purified by agarose gel electrophoresis, ligated
into the pUWL201pw vector, and transformed into S. lividans TK64 protoplasts.
The plasmid encoding the model enzyme LipK was also used to transform a
different host, Streptomyces albus (S. albus). The respective S. lividans or S.
albus strain was then cultured in R2YE media with the selective antibiotic
thiostrepton and the recombinant proteins were partially purified by nickel affinity
column (Fig. 3.1A-D and F). All five proteins proved soluble in S. lividans; LipK
was also soluble in S. albus.
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Figure 3.1. Expression of recombinant putative SHMTs. (A) SDS-PAGE
analysis of partially purified His6-Orf25 from Streptomyces lividans TK64 (lane 2,
expected MW of 50.24 kD). (B) SDS-PAGE analysis of partially purified His6Mra14 from Streptomyces lividans TK64 (lane 2, expected MW of 50.1 kD). (C)
SDS-PAGE analysis of partially purified His6-CapH from Streptomyces lividans
TK64 (lane 2, expected MW of 50.4 kD). (D) SDS-PAGE analysis of purified
His6-LipK from Streptomyces lividans TK64 (lane 2, expected MW of 50.1 kD).
(E) SDS-PAGE analysis of partially purified His6-LipK(K235A) (lane 2, expected
MW of 50.1 kD). (F) SDS-PAGE analysis of partially purified His6-LipK from
Streptomyces albus (lane 2, expected MW of 50.1 kD). The expected molecular
weight for each of the above proteins was calculated to include an engineered Nterminal His6-tag (5 kD) and lane 1 represents molecular weight standards
purchased from BioRad.
	
  
	
  
3.1.3 Site directed mutagenesis of the model enzyme LipK
Due to the importance of the Lys residue in the formation of the PLP binding
motif in SHMT reactions, a His6-LipK(K235A) mutant was generated. PLP
dependent enzymes follow a mechanistic pathway that can be monitored by
UV/Vis spectroscopy. Both the known SHMTs and LTAs involve the formation of
an internal aldimine (holo-enzyme) upon which an amino acid then binds forming
an external aldimine. Both the internal and external aldimine display a unique
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absorbance at 425 nm. (4, 43) Mutation of the lysine residue would obliterate
formation of the PLP bound intermediate and formation of the external aldimine
to yield an inactive enzyme. The lipK-(K235A) mutant was generated from
pET30-lipK using Quikchange technology and sequenced to 100% identity. The
lipK-(K235A) plasmid was then digested with NdeI and HindIII and ligated into
the pUW201pw vector for transformation into S. lividans TK64 protoplasts. The
generated LipK(K235A) mutant	
  was heterologously expressed in S. lividans TK64 and also proved to be soluble (Fig. 3.1E).
	
  
3.2. Characterization of theoretical SHMTs
With the soluble proteins in hand, we were able to test for enzymatic activity and
determine the role of the putative SHMTs in the biosynthesis of icaprazamycin
and capuramycin-like compounds. Previous work in our lab has indicated that the
precursor for the putative SHMTs was likely uridine-5ʹ′-aldehyde (UA), the product
of the α-ketoglutarage:UMP dioxygenase LipL (38). We hypothesized that these
enzymes used UA to add a glycyl unit to produce 5ʹ′-C-glycyluridine (GlyU) (Fig.
3.2).
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Figure 3.2 Reaction of putative SHMTs in caprazamycin and capuramycinrelated compound biosynthesis. The formation of GlyU (1) utilizing uridine-5ʹ′aldehyde (2) as a substrate and the putative SHMTs.
	
  
	
  
	
  
3.2.1.1

Substrate and activity testing of the putative SHMTs Mra14,

LipK, CapH, and Orf25
In order to test The hypothesized function of the putative SHMTs, we synthesized
the potential substrate UA (Fig. 3.3) and incubated it with 5 µM of each putative
SHMT Mra14, LipK, Orf25, and CapH, with Gly, or other L-amino acids as
potential co-substrates.
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Figure 3.3. The substrate Uridine-5′-aldehyde NMR. The synthesis of uridine5′-aldehdye followed a two-step procedure that was previously described.(38)
MS and 1H- and 13C-NMR spectra (above) were consistent with this report.

3.2.1.2 Substrates and enzymatic activity of the putative SHMTs from
caprazamycin-like compounds muraminomicin and A-90289.
The caprazamycin-related compounds has a core structure of a β-hydroxy-αamino acid 5′-C-glycyluridine (GlyU). Due to the SHMTs C-C bond forming
ability, the putative SHMTs Mra14 and LipK from caprazamycin-related
compounds were initially tested for enzymatic activity using UA as well as the cofactor PLP with the expectation that GlyU would be formed. Gly and Ser were
initially tested as glycyl unit donors for incorporation onto the UA intermediate.
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3.2.1.2a

Substrates and enzymatic activity of Mra1

Enzymatic activity of the putative SHMT Mra14 from the muraminomicin
biosynthetic gene cluster was tested using 2.0 mM UA, 0.1 mM PLP, and 10.0
mM of a variety of amino acid donors in 50 mM potassium phosphate buffer (pH
7.5). Individual reactions were prepared and incubated at 30°C for 2 hr, 6 hr, and
18 hr and terminated by spin column filtration. The reactions were then analyzed
by reverse-phase HPLC utilizing a linear acetonitrile gradient. No activity was
observed with Gly or Ser as amino acid donors. In contrast, enzymatic activity
was found using UA and L-Thr as the donor with PLP as a co-factor (Fig. 3.4A).
3.2.1.2b

Substrates and enzymatic activity of LipK

The putative SHMT LipK from the A-90289 biosynthetic gene cluster was also
tested for activity using 2.0 mM UA, 0.1 mM PLP, and 10.0 mM of a variety of
amino acid donors in 50 mM potassium phosphate buffer (pH 7.5). Once again,
the individual reactions were prepared and incubated at 30°C for 2 hr, 6 hr, and
18 hr and terminated by spin column filtration and analyzed by reverse-phase
HPLC utilizing a linear acetonitrile gradient. Identical to Mra14, the only
enzymatic activity was seen utilizing UA, and L-Thr as substrates with co-factor
PLP (Fig. 3.4B).
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Figure 3.4. Verification of enzymatic activity of the putative SHMTs isolated
from the biosynthetic gene cluster of caprazamycin-related compounds.
Reactions were carried out in 50 mM potassium phosphate buffer (pH 7.5),
0.1mM PLP, 10 mM L-Thr or Gly, and 2.0 mM UA. (A) Enzymatic activity
involving the putative 5 µM SHMT, Mra14, from the muraminomicin biosynthetic
gene cluster. No activity was seen with the amino acid donor Gly while product
formation was observed at 1.28 min with L-Thr. (B) Enzymatic activity involving
the putative 5 µM SHMT, LipK, from A-90289 biosynthetic gene cluster. Again,
no activity was seen with the amino acid donor Gly while product formation was
observed at 1.28 min with L-Thr.
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3.2.2 Characterization of enzymatic product using LipK as the model
enzyme
HPLC analysis revealed the formation of a new peak, but only with the substrates
UA, L-Thr, and the cofactor PLP. In contrast incubation of the mutant protein
LipK(K235A) with UA, L-Thr, PLP, and other amino acids in place of L-Thr
revealed no new peak. The lack of activity and utilization of any other amino acid
donor verifies the specificity of this enzyme mutagenesis of the lysine residue
indicates the necessity of PLP binding and internal aldimine formation to initiate
the catalytic mechanism (Fig. 3.5 and Fig. 3.20). Using a large-scale reaction
with LipK, the product was partially purified by reverse-phase HPLC.
Subsequentially, a boronic acid affinity column was utilized to bind the cishydroxyl groups located on the 2ʹ′ and 3ʹ′ positions of the ribose of the expected
enzymatic product.
3.2.2.1

LC-MS anaylsis of LipK product

The purified product was verified for purity by HPLC analysis and submitted for
LC-MS analysis (Fig. 3.6). LC-MS revealed a (M – H)- ion at m/z = 315.9
consistent with the molecular formula C11H13N3O8 of GlyU (expected m/z =
316.1) (Fig. 3.6B and Fig. 3.6C).
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Figure 3.5. HPLC analysis of the reaction catalyzed by LipK. Using 2 with
co-substrate Gly or Ser (I), L-Thr without exogenous PLP (II), L-Thr (III), and L-Thr
with LipK (K235A) (IV). AU, absorbance units; A260, absorbance at 260 nm.
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Figure 3.6. LC-MS analysis of the LipK product, 1. (A) HPLC trace of
enzymatically prepared product following purification using reverse-phase
chromatography and boronic acid affinity chromatography. (B) Mass spectrum for
the peak eluting at t = 3.3 min yielding an (M - H)- ion consistent with the
molecular formula of 1. (C) High resolution mass spectrum of purified 1 yielding
an (M - H)- ion consistent with the molecular formula of 1. A260, absorbance at
260 nm.
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3.2.2.2

1D and 2D NMR spectroscopic analysis

Approximatedly 10 mg of purified product was lyophilized and re-suspended in
DMSO for 1D and 2D NMR analysis.
3.2.2.2a 1D Spectroscopic analysis
In an effort to easily identify the 1ʹ′, 5, 5ʹ′, and 2ʹ′ peaks, a DMSO solvent was
chosen as the solvent (Fig. 3.7). The spectroscopic analysis is consistent with
that of the expected product (5'S, 6'S)-GlyU (Fig. 3.7 – 3.9 ) which was compared
to synthetic NMR data acquired with (5'S, 6'S)-GlyU.
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Figure 3.7. 1D NMR spectra of the LipK product, 1. (A) 1H-NMR spectrum of
1 following a two-step purification of reverse-phase chromatography and boronic
acid affinity chromatography. DMSO was utilized as a solvent to minimize the
interference of the water peak that was difficult to avoid due to the highly
hygroscopic nature of 1. (B) 13C-NMR spectrum of 1 with contaminating glycerol
that originated from the enzyme storage solution and formate that was used to
elute 1 from the immobilized boronic acid resin.
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3.2.2.2b

2D Spectroscopic analysis

Figure 3.8. 1H-13C gHSQC NMR spectrum of the LipK product, 1.
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Figure 3.9. 1H-13C gHMBC NMR spectrum of the LipK product, 1.
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3.2.3 Phosgene modification and HR-ESI-MS, 1D, and 2D spectroscopic
analysis of the LipK enzymatic product and synthetic controls
Further stereochemical assignment of the 5' and 6' position of the enzymatic LipK
product by phosgene modification was done. Phosgene (COCl2), known
primarily for its use in WWI as a poisonous choking agent and for its use in
polyurethane synthesis, has the ability to lock in the stereochemistry of βhydroxy-α-amino acids, and therefore compound 1 by reacting with primary
amine and adjacent oxygen center. Phosgene initially reacts with the nitrogen
lone pair forming a collapsible intermediate, which gives a stable carbomoyl
chloride derivative and can sequentially undergo dehydrohalogenation.
Reactions with α-amino acids and phosgene afford oxazolidine-2,5-diones,
commonly called N-carboxy anhydrides or Leuchs’ anhydrides without altering
the stereochemistry of the original stereocenters of the initial substrate (55, 56).

Synthetic controls of the (5'S, 6'S)-GlyU, (5'S, 6'R)-GlyU, and (5'R, 6'S)-GlyU
compound were obtained from the lab of Dr. Christian Ducho. Both the synthetic
and enzymatic LipK product were modified with phosgene and were then
analyzed by HPLC and NMR spectroscopy (Fig. 3.10 – 3.14).
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3.2.3.1

HPLC and MS analysis of phosgene modified 1 controls

and the LipK enzymatic product
HPLC analysis of the phosgene-modified compounds revealed identical elution
times of the phosgene-modified enzymatic product and that of the phosgene
modified (5'S, 6'S)-GlyU diastereomer (Fig. 3.10). The new peaks were collected
and subjected to MS analysis. The new peaks revealed (M – H)- ions of m/z =
341.7 and 367.6. These masses are consistent with that of either a single
phosgene modification (m/z = 343) or a double phosgene modification (m/z =
369) (Fig. 3.11).
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Figure 3.10.
Comparative analysis of enzymatic and synthetic 1
diastereomers. (A) HPLC analysis of pure phosgene-modified (5'S,6'S)-1 that
was prepared by enzymatic synthesis and confirmed by NMR spectroscopy (I),
(5'S,6'S)-1 prepared by chemical synthesis (black, solid line) and spiked with an
equimolar amount of enzymatic (5'S,6'S)-1 (blue, dashed line) (II), crude mixture
of (5'S,6'S)-GlyU that was prepared by enzymatic synthesis and modified with
phosgene (III), crude mixture of (5'S,6'S)-1 that was prepared by chemical
synthesis and modified with phosgene (black, solid line) and spiked with
authentic, enzymatically produced phosgene-modified (5'S,6'S)-1 (red, dashed
line) (IV). (B) HPLC analysis of pure phosgene-modified (5'S,6'S)-1 (I), synthetic
(5'R,6'S)-1 (II), phosgene-modified (5'R,6'S)-1 (III), synthetic (5'S,6'R)-1 (IV), and
phosgene-modified (5'S,6'R)-1 (V). A260, absorbance at 260 nm.
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Figure 3.11. Phosgene modification of 1. (A) Semipreparative HPLC analysis
of purified 1 prepared enzymatically that was reacted with phosgene to yield two
major products with the expected mass spectrum for modification with (B) one or
(C) two molecules of phosgene. A260, absorbance at 260 nm.
	
  
3.2.3.2

1D NMR analysis of the phosgene modified LipK

enzymatic product
1

H-NMR analysis of the phosgene-modified enzymatic product indicated a J

coupling of ~5 Hz which is consistent with the MM2 ChemBio3D prediction
suggesting a dihedral angle of 112° for phosgene-modified threo diastereomer
(5'S,6'S)-GlyU under acidic conditions. In contrast, the erythro diastereomers are
predicted to contain dihedral angles of ≤32° which is approximate to J values >8
Hz. The remaining (5'R, 6'R) threo diastereomer was ruled out due to the
necessity of the dihedral angle of 160° which correlates to a ~12 Hz coupling
constant (Fig. 3.12).
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Figure 3.12. 1D NMR spectrum of phosgene-modified (5'S,6'S)-1. (A) 1H
NMR spectrum of (5'S,6'S)-1 prepared enzymatically and modified with
phosgene. Predictions following MM2 energy minimization with ChemBio3D
suggest a dihedral angle of 112° for	
  phosgene-modified (5'S,6'S)-1 under acidic
conditions that were utilized to obtain purified material for NMR. This dihedral
angle is consistent with the J value of 5 Hz obtained from the 1H-NMR spectrum,
suggesting a threo configuration and overall stereochemical assignment as
(5'S,6'S)-1. [Note that the ribofuranose component changes the priority at C-5’
compared to C-3 of (2S,3R)-Thr, the threo diastereomer of L-Thr that serves as
the substrate for LipK]. The erythro diastereomers are predicted to have dihedral
angles of ≤ 32° that would yield J values of > 8 Hz, and the remaining threo
diastereomer [(5'R,6'R)-1] is predicted to have a dihedral angle of 160° that
would yield a J value of ~12 Hz. (B) 13C NMR spectrum of (5'S,6'S)-1 prepared
enzymatically and modified with phosgene.
	
  

	
  

57

3.2.3.3
2D NMR analysis of the phosgene modified LipK
enzymatic product

Figure 3.13. gCOSY NMR spectrum of phosgene-modified (5'S,6'S)-1.
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Figure 3.14.
1.

	
  

1

H-13C gHMBC NMR spectrum of phosgene-modified (5'S,6'S)-
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3.2.4 Identification of enzymatic activity with capuramycin-related
compounds by HPLC analysis
Bioinformatic analysis revealed both the caprazamycin and capuramycin-related
compounds contain lipL and an orf encoding the putative SHMT homolog. This
suggests a strong correlation in the biosynthesis of the core structures where
GlyU is an intermediate of the uridine-5ʹ′--carboxamide (CarU) found in
capuramycin-related antibiotics.
3.2.4.1

Substrates and enzymatic activity of Orf25

The putative SHMT, Orf25, from the capuramycin-like compound A-102395, was
tested for activity using 2.0 mM UA, 0.1 mM PLP, and 10.0 mM of a variety of
amino acid donors in 50 mM potassium phosphate buffer (pH 7.5). Individual
reactions were incubated at 30°C and terminated by spin column filtration at 2 hr,
6 hr, and 18 hr time points. The control reaction and subsequent reactions
containing 5 µM of Orf25 were then analyzed by reverse-phase HPLC using a
linear gradient of water to acetonitrile. The control reaction containing all the
components except enzyme showed elution of the UA substrate at ~1.98 min.
Similarly to LipK and Mra14, there was no activity seen with the amino acids Gly
or Ser, the primary hypothetical amino acid donor. However, a new peak was
seen with the partially purified Orf25 when using L-Thr as previously observed
with the other enzymes. HPLC analysis revealed the enzymatic product eluted at
~1.28 min (Fig. 3.15A).
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3.2.4.2

Substrates and enzymatic activity of CapH

The next putative SHMT of interest from the capuramycin-like compound A503083 biosynthetic gene cluster, CapH, was tested for activity. Again, 2.0 mM
UA, 0.1 mM PLP, and 10.0 mM of a variety of amino acid donors in 50 mM
potassium phosphate buffer (pH 7.5) containing 5 µM of CapH were tested for
enzymatic activity. Individual reactions were prepared and incubated at 30°C for
2 hr, 6 hr, and 18 hr and terminated by spin column filtration. The reactions were
then analyzed by reverse-phase HPLC utilizing a linear acetonitrile gradient.
Once again, the control reaction containing all substituents except enzyme
showed elution of the UA substrate at ~1.98 min and the primary hypothetical
amino acid donors Gly or Ser showed no activity in any of the reactions. In
contrast, and similarly to Orf25, HPLC analysis again revealed enzymatic activity
with the amino acid L-Thr with the enzymatic product eluting at ~1.28 min (Fig.
3.15B), consisten with GlyU as the product.
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B

Figure 3.15. Verification of enzymatic activity of the putative SHMTs
isolated from the biosynthetic gene cluster of capuramycin-related
compounds. Reactions were carried out in 50 mM potassium phosphate buffer
(pH 7.5), 0.1mM PLP, 10 mM L-Thr or Gly, and 2.0 mM UA. (A) Enzymatic
activity involving the putative 5 µM SHMT, Orf25, from A-102395 biosynthetic
gene cluster. No activity was seen with the amino acid donor Gly while product
formation was observed at 1.28 min with L-Thr. (B) Enzymatic activity involving
the putative 5 µM SHMT, CapH, from A-503083 biosynthetic gene cluster.
Again, no activity was seen with the amino acid donor Gly while product
formation was observed at 1.28 min with L-Thr.
	
  
3.2.5

	
  
Comparison of enzymatic activity of putative SHMTs

Due to the high similarity in amino acid sequence, as well as a key lysine residue
located at ~235 aa found in each enzyme, the selection of preferred substrates
by each enzyme indicates an identical catalytic function of the putative SHMTs
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(Table 3.2). Comparison of the putative SHMTs utilizing UA, and L-Thr as
substrates and PLP as a co-factor indeed gave identical HPLC chromatographs
(Fig. 3.16). This is further evidence that the putative SHMTs are involved in the
biosynthesis of the core unit of both the caprazamycin and capuramycin-related
compounds GlyU and CarU respectively. Importantly, the results in total have
led us to functionally assign these enzymes as LP-dependent UA: L-Thr
transaldolases.

Table 3.2. Transaldolase sequence comparison. Comparison of the amino
acid sequence of the individual putative SHMTs. %Identical/%Similar.
	
  
LipK	
  
CapH	
  
Mra14	
  
Orf25	
  

LipK	
  
X	
  
45/47	
  
81/82	
  
45/47	
  

CapH	
  
45/47	
  
X	
  
46/48	
  
79/80	
  

Mra14	
  
81/82	
  
46/48	
  
X	
  
45/47	
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Orf25	
  
45/47	
  
79/80	
  
45/47	
  
X	
  

	
  
Figure 3.16. Transaldolase activity utilizing L-Thr and UA as primary
substrates. Reactions were carried out in 50 mM potassium phosphate buffer
(pH 7.5), 0.1mM PLP, 10 mM L-Thr or Gly, and 2.0 mM UA. The control reaction
reflects reaction conditions lacking any enzyme. LipK, Mra14, Orf25, and CapH
were individually tested by addition of 5 µM, run at 30°C, and terminated by spin
column after 18 hours. The substrate UA elutes at ~1.89 min while the enzymatic
product of each of the afore mentioned enzymes elutes at ~1.29 min. No activity
was seen utilizing any other amino acid donor.

3.3. Isotopic feeding experiments for the capuramycin-like compound A503083
The results suggest GlyU is an intermediate in the biosynthesis of the uridine-5ʹ′carboxamide (CarU) core in the capuramycin-related compound biosynthesis. In
order to provide additional evidence for the shared biosynthetic mechanism in
capuramycin and carazamycin-related compounds, isotopic tracer experiments
were executed employing the strain that produces A-503083. [1-13C]Gly or [213

C]Gly and L-[13C4, 15N]Thr were used with the expectation that the first two

would serve as negative controls while the last would lead to enrichment
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3.3.1 Isotopic feeding of [1-13C]Gly or [2-13C]Gly to the A-503083 B strain
The isotopically labeled Gly was fed into the producing strain of A-503083 B, the
aminocaprolactam-containing and major congener of the A-503083 compounds
(Fig. 3.17A). There was no significant enrichment observed for A-503083 B
except for a 6% enrichment of the 3ʹ′-O-methyl group when fed the [2-13C]Gly into
the producing strain	
  (Fig. 3.17B-D). This result is consistent with previous Gly
tracer studies for other Streptomyces O-methylated metabolites (57).
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Figure 3.17. Isotopic tracer experiments using 13C-Gly. (A) Structure of A503083 B, the 6'''-desmethyl derivative of A-503083 A. (B) 13C-NMR spectrum of
A-503083 B obtained without feeding (natural abundance 13C). (C) 13C-NMR
spectrum of A-503083 B	
  obtained with [1-13C]Gly feeding. (D) 13C NMR spectrum
of A-503083 B obtained with [2-13C]Gly feeding.
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3.3.2 Isotopic feeding of L-[13C4, 15N]Thr into the strain producing A-503083
F
The isotopically labeled compound L-[13C4, 15N]Thr was fed into the producing
strain of A-503083 F, the deaminocaprolactam derivative of A-503083 B and a
minor congener produced by the strain (Fig. 3.18A). In contrast to the [1-13C]Gly
and [2-13C]Gly experiment, there was a 15% enrichment at the C-6ʹ′ position (Fig.
3.18B-D). Incorporation at this position is consistent with the direct incorporation
of L-Thr by means of a transaldolase mechanism. We also observed a C-6ʹ′
doublet within the 13C spectrum (JCN = 18 Hz) indicative of a preserved C-N bond
from L-Thr during biosynthesis of CarU (Fig. 3.18E).
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Figure 3.18. Isotopic tracer experiments using L-[13C4,15N]Thr. (A) Structure
of A-503083 F, the deaminocaprolactam derivative of A-503083 A. (B) HPLC
analysis of the purified A-503083 F obtained without feeding (natural abundance
13
C) and with L-[13C4,15N]Thr feeding. (C) Mass spectra for the peak eluting at t =
5.2 min, comparing A-503083 F isolated without feeding (blackbars) and with L[13C4,15N]Thr feeding (redbars). (D) 13C-NMR spectrum of A-503083 F obtained
without feeding (natural abundance 13C). (E) 13C-NMR spectrum of A-503083 F
obtained withL-[13C4,15N]Thr feeding.
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3.4.

Biochemical analysis of the model enzyme LipK

3.4.1 Co-factor determination of the model enzyme of LipK
A useful characteristic of PLP-dependent enzymes is the unique UV/VIS
spectrum associated with the binding of the co-factor and formation of catalytic
intermediates. During the reaction coordinate formation of the internal aldimine,
or holo-enzyme, followed by amino acid binding to form the external aldimine
exhibits a UV maximum near 425 nm. Both SHMTs and LTAs elicit a UV
maximum near 425 nm upon binding of the B6 derived cofactor PLP and
formation of the internal aldimine (Fig.3.19A). (4, 43). Contrastingly, LTA forms a
quininoid intermediate upon Cα abstraction of Gly shifting the UVmax to 492 nm,
while SHMTs retaining the same profile until THF binding to form a ternary
complex, thus shifting the maximum to 500 nm (Fig. 3.19A).

Analysis of EcGlyA, EcLTA, and LipK revealed a UV/Vis spectra consistent with
PLP bound to the protein as purified. The model enzyme LipK originating from
both S. lividans TK64 and S. albus displayed a UVmax at 416 nm (Fig. 3.19B and
Fig. 3.19F) which was absent in the LipK(K235A) mutant (Fig. 3.19F). The
EcLTA displayed a maximum absorbance at 421 nm (Fig. 3.19C), while the
EcGlyA at 425 nm (Fig. 3.19D). As expected, upon addition of Gly, the EcLTA
shifted the UVmax to 492 nm (Fig. 3.19C) and the EcGlyA UVmax shifted to 500
nm upon the addition of both THF and Gly (Fig. 3.19D). These shifts in UVmax
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are both consistent with the formation of a quininoid intermediate. In contrast,
addition of either Gly, THF, or both did not alter the UVmax of LipK (Fig. 3.19E).
This data suggests that LipK has unique catalytic properties differing from those
of EcGlyA and EcLTA.
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Figure 3.19. UV/Vis spectra for intermediates and the potential
intermediates of the PLP-dependent enzymes under analysis. (A) Formation
of the internal aldimine with the binding of the apo-enzymes to PLP generating
the holo-enzyme (I) followed external aldimine formation by Gly binding (II). A
quininoid intermediate is observed by UV/VIS spectroscopy due to deprotonation
at the α-carbon within the active site of LTA. (III). In contrast, SHMT binding of the
substrate analogues of N5,N10-methylene tetrahydrofolate (THF) such as THF to
form a ternary complex that undergoes deprotonation at the α-carbon of Gly to
yield a quininoid intermediate (IV). However, no UV/Vis spectral changes were
identified with LipK therefore precluding the assignment of any intermediates that
are depicted. (B) UV/Vis spectrum of LipK isolated from Streptomyces albus. (C)
UV/Vis spectrum of EcLTA as isolated (holo-EcLTA), following the addition of Gly
(+Gly), and following addition of Gly with 2 (+Gly and 2). The reduction in the
peak at 492 nm following the addition of 2 suggests either a reaction is occurring
or 2 binding is promoting re-formation of aldimine II, in both cases preventing the
accumulation of a quininoid intermediate. As subsequently determined, the
inability to observe any product by HPLC is consistent with the latter. (D) UV/Vis
spectrum of EcGlyA as isolated (holo-EcGlyA), following the addition of Gly
(+Gly), and following addition of Gly with THF (+Gly and THF). (E) UV/Vis
spectrum of LipK as isolated (holo-LipK), following the addition of Gly (+Gly), and
following addition of Gly with 2 or THF (+Gly and 2 or THF). (F) The UV/Vis
spectra of recombinant LipK and point mutant isolated from S. lividans TK64. AU,
absorbance units.
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3.4.2 Specificity and biochemical properties of LipK
In order to develop assays capable of measuring LipK activity, optimal reaction
conditions were determined. By identifying optimal pH, buffer conditions, and
potential substrates, we were able to determine conditions suitable for kinetic
analysis. Kinetic analysis utilized the formation of a secondary product during
the LipK reaction, acetaldehyde.
3.4.2.1 Optimization of LipK enzymatic activity
3.4.2.1a L-Thr specificity for LipK activity
We first explored LipK activity with different α-amino acids and detection by
HPLC. The only activity seen was that utilizing L-Thr as the amino acid donor.
The lack of activity with proteinogenic α-amino acids, commercially available LThr diasteromers, and Thr analogues (Fig. 3.20) indicates the high specificity for
L-Thr.

3.4.2.1b Optimal pH and buffer for LipK activity
A variety of buffers capable of maintaining various pH profiles was tested to
determine the optimal pH for activity. Succinate, citrate, phosphate, Tes, Hepes,
and Tris buffers were prepared in pH profiles ranging from 3-10 and tested. The
pH profile for LipK resembles a bell shaped curve under initial velocity conditions
and maintained an optimal pH activity at 7.5 with the optimal buffer being Tes
(Fig. 3.21A).
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3.4.2.1c Optimal salt concentration for LipK activity
The monovalent cations K+ and Na+ have shown activation of enzymatic activity
by enhancing the affinity of the enzyme for the substrate (58). Therefore,
monovalent cation concentration was tested between 0.001-10000 mM.
Monovalent ions slightly changed the activity up to 100mM and then began to
decrease activity (Fig. 3.21B).

	
  
Figure 3.20. HPLC analysis to probe the substrate specificity of LipK. The
reactions were carried out in 50 mM HEPES (pH 7.5), 2 mM 2, 5 mM indicated
co-substrate (all α-amino acids), 0.1 mM PLP, and 2 µM LipK at 30 °C for 1 h
prior to termination. Product formation was monitored using the Agilent HPLC
system with an Eclipse XDB-C18 column. (o) 2 (•) 1. A260, absorbance at 260 nm.
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Figure 3.21. Activity optimization for LipK. (A) pH profile of LipK. The activity
was assessed in reactions containing 50 mM buffer,2 mM uridine-5'-aldehyde, 5
mM L-Thr,0.1 mM PLP, and 2 µM LipK at 30 °C under initial velocity conditions.
Product formation was assessed by HPLC. (B)Activity of LipK with monovalent
salts using 50 mM TES (pH 7.5)and the conditions indicated in A.

3.4.2.2

Assay development for enzymatic activity

After optimizing conditions for enzymatic activity for LipK, we tested for L-Thr
dependent retro-aldol activity in which we utilized the formation of acetaldehyde
during the reaction to develop an assay amicable to kinetic analysis.
Saccharomyces cerevisiae aldehyde dehydrogenase (ADH, EC 1.2.1.3)
efficiently utilizes acetaldehyde as a substrate for oxidation by reduction of βNAD+ (Fig. 3.22). To verify the formation of acetaldehyde, we also compared
results to that of EcLTA and EcGlyA.
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Figure 3.22. The LipK-catalyzed reaction and coupling with
aldehyde dehydrogenase (ADH).

First, we ensured conditions for ADH activity did not interfere with the activity of
the LipK, EcLTA, and EcGlyA (Fig. 3.23). This assay revealed that a retro-aldol
reaction was catalyzed solely with L-Thr and LipK, EcLTA, and EcGlyA yielding
activities of (1.3 ± 0.2) x 10-2, 1.2 ± 0.2, and (5.7 ± 0.4) x 10-4 µmol/min/mg,
respectively (Fig. 3.24 and 3.25A).
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B

Figure 3.23. Assay Development for LipK. (A) HPLC analysis of the LipK
reaction starting with 2 after 2 h reactions with omission of L-Thr (I), all necessary
reaction components (II), reaction components plus 1 mM β-NAD+ (III), reaction
components plus 1 mM β-NAD+ and 1 mM DTT (IV), reaction components plus 1
mM β-NAD+, 1 mM DTT, and 100 mM KCl (V). The results demonstrate that LipK
activity is not affected by β-NAD+, DTT, or KCl at these concentrations. Reactions
were monitored using the Agilent HPLC system with an Eclipse XDB-C18
column. β-NAD+, β−nicotinamide adenine dinucleotide, oxidized form; oxDTT,
oxidized dithiothreitol; A260, absorbance at 260 nm. (B) UV/Vis spectroscopic
analysis of the LipK and aldehyde dehydrogenase (ADH)-coupled reaction
monitoring the reduction of β-NAD+. ADH did not oxidize 2, pyridoxal-5'phosphate (PLP), nor TES buffer, and oxidation activity of acetaldehyde was not
affected by the necessary components for LipK activity. 1X corresponds to 0.004
U of ADH. A340, absorbance at 340 nm.
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Figure 3.24. L-Thr aldolase activity. Reactions were conducted in 50 mM TES
(pH 7.5), 100 mM KCl, 1 mM DTT, 0.1 mM PLP, 10 mM L-Thr, 2 mM β-NAD+ at
30 °C (A) LipK at 33 µg (▲), 62.5 µg (■) and 96 µg (●) yielding a specific activity
of (1.3 ± 0.2) x 10-2 µmol/min/mg. (B) EcLTA at 0.12 µg (▲), 0.5 µg (■) and 1.7
µg (●) yielding a specific activity of 1.2 ± 0.2 µmol/min/mg. (C) EcGlyA at 300 µg
(▲), 750 µg (■) and 1180 µg (●) yielding a specific activity of (5.7 ± 0.4) x 10-4
µmol/min/mg. A340, absorbance at 340 nm.
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Although the detection of acetaldehyde with LipK was surprising, the rate of
retro-aldol activity catalyzed by LipK was significantly increased upon an
equimolar addition of UA (Fig. 3.25A), which suggests that the normal catalytic
cycle involves an initial binding of L-Thr and formation of a ternary complex. The
single-substrate kinetics experiments utilizing LipK displayed the typical
Michaelis-Menten kinetics in regards to UA and yielded constants of Km = 29.2 ±
9.5 mM and kcat = 40 ± 4 min-1 (Fig. 3.25B). However, while the high Km for UA
precluded an accurate single-substrate kinetic analysis with respect to varied LThr, the bisubstrate kinetic analysis was consistent with LipK utilizing a
sequential mechanism more characteristic of bona fide SHMTs despite the
production of acetaldehyde in the absence of UA (Fig. 3.25C) (54).
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Figure 3.25. Kinetic analysis of LipK. (A) UV/Vis spectroscopic analysis of the
L-Thr retro-aldol-type reaction catalyzed by LipK in the absence or presence of
10 mM 2. Each line represents an independent reaction with 2 added at the
indicated time. A340, absorbance at 340 nm. (B) Single-substrate kinetic analysis
with 30 mM L-Thr and variable 2. (C) Bisubstrate kinetic analysis using 1 mM (■),
3 mM (▲), and 60 mM (●) 2.
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3.5. Exploration of EcGlyA and EcLTA as L-threonine Transaldolases
The initial bioinformatics analysis of the four enzymes studied in this dissertation
gave the highest similarity to PLP dependent serine hydroxymethyltransferases.
However, the actual function is revealed to be an L-Thr transaldolase. Knowing
that the putative SHMT LipK is actually a transaldolase, we decided to test both
EcGlyA and EcLTA, well characterized SHMT and LTA respectively, for
transaldolase activity.

3.5.1 Enzymatic activity with L-Thr and UA as primary substrates
The initial experiment combined PLP, TES buffer, Gly, and UA with either
EcGlyA or EcLTA and subjected to HPLC analysis. (43, 59) Initial screening
revealed no activity with Gly, however a low amount of activity with L-Thr was
observed (Fig. 3.26). The new peaks had identical retention time and UV
spectrum to the LipK product, GlyU. The stereochemistry of this reaction product
is under investigation.
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Figure 3.26. Detection of potential (trans)aldolase activity of EcGlyA and
EcLTA. HPLC analysis of 18 h reactions containing 5 µM enzyme and 2 with
control (no enzyme, I), EcLTA with Gly (II), EcLTA with L-Thr (III), EcGlyA with
Gly (IV), EcGlyA with L-Thr (V), and LipK with L-Thr (VI). (o) 2, (●) new peak coeluting with 1. A260, absorbance at 260 nm.
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3.5.2 Enzymatic activity with L-Thr and 2-pyridine-carboxaldehyde as
primary substrates
Due to the enzymatic activity seen with UA and L-Thr, with either EcGlyA and
EcLTA in comparison to LipK, the potential L-Threonine transaldolase activity of
EcGlyA and EcLTA was further explored with the alternative aldehyde
substrates. The commercially available substrates 2-pyridine-carboxaldehyde
and L-Thr were tested for enzymatic activity with EcGlyA and EcLTA, using
reverse-phase HPLC and MS for detection and analysis.

3.5.2.1 HPLC analysis of enzymatic reactions involving EcGlyA (EcSHMT),
EcLTA, and 2-pyridine-carboxaldehyde
Reactions incorporating 0.1 mM PLP, 10.0 mM L-Thr, 2.0 mM 2-pyridinecarboxaldehyde, and 5 µΜ enzyme were incubated for 18 h. The reactions were
analyzed by reverse-phase HPLC chromatography following a linear acetonitrile
gradient. The control reaction lacking any enzyme shows elution of the 2pyridine-carboxaldehyde at ~1.93 min. Reactions containing 5 µM of the
specified enzyme indicate enzymatic activity by the formation of a new peak at
~1.53 min. Both EcGlyA and EcLTA show identical chromatographs to that of
the reaction containing LipK (Fig. 3.27A).
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3.5.2.2 MS analysis of enzymatic reactions involving EcGlyA, EcLTA, and
2-pyridine-carboxaldehyde.
The new peak was collected and subject to HPLC analysis for purity and MS
analysis for preliminary identification of the product. The EcGlyA product
appeared pure while the EcLTA product showed only minor contamination in the
chromatograph (Fig. 3.27D and Fig. 3.27E). Interestingly, both the EcGlyA
product and the EcLTA product showed a (M – H)+ ion at m/z = 183.2 (Fig. 3.27B
and Fig. 3.27C), consistent with that of 4 (expect m/z = 182), the L-Thr
transaldolase product of 2-pyridine-carboxaldehyde and L-Thr (Fig. 3.27F). The
structure and stereochemical assignment of the product is under investigation.
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Figure 3.27. HPLC and MS analysis of EcSHMT and EcLTA transaldolase
activity utilizing L-Thr and 2-pyridine-carboxaldehyde as primary
substrates. (A) HPLC analysis of 18 h reactions with no enzyme in the control,
5 µM EcLTA, 5µM EcGlyA, and 5 µM LipK. Abs(254), absorbance at 254 nm.
(B) Mass spectrum for the peak eluting at t = 1.53 min from the enzymatic
product of 2-pyridine-carboxaldehyde, L-Thr, PLP, and EcGlyA. The product
yields an ion of mass (M – H)+ consistent with the molecular formula of 4. (C)
Mass spectrum for the peak eluting at t = 1.53 min from the enzymatic product of
2-pyridine-carboxaldehyde, L-Thr, PLP, and EcLTA. The product yields an ion of
mass (M – H)+ consistent with the molecular formula of 4. (D) HPLC trace of the
EcGlyA enzymatically prepared product following purification using reversephase chromatography. (E) HPLC trace of the EcLTA enzymatically prepared
product following purification using reverse-phase chromatography. (F) Lthreonine transaldolase activity incorporating L-Thr onto 2–pyridinecarboxaldehyde.
Copyright © Sandra Hummel Barnard 2013	
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Chapter Four

Summary
The caprazamycin and capuramycin-related compounds A-90289,
muraminomicin, A-503083, and A-102395 are potent MraY inhibitor compounds
with great potential for antibacterial use within the clinical setting. Their complex
and novel structures help to delay the onset of resistance while their nonmammalian homolog targets are specific for gram-positive and gram-negative
peptidoglycan cell wall formation. By investigating the biosynthetic pathway
utilized in the formation of these compounds, we were able to identify enzymatic
homologs suggesting similar biosynthetic pathways in these two families.
Characterization of these shared enzymatic homologs revealed novel and
interesting chemistry.

Herein we have described the novel chemistry utilized by the putative SHMTs
within the caprazamycin and capuramycin-related compounds that catalyze C-C
bond formation that is necessary in assembling the high carbon furanoside. The
MraY translocase I inhibitor compounds A-90289 isolated from Streptomyces sp.
SANK 60405, muraminomicin isolated from Streptosporangium amethystogenes
SANK 60709k, A-503083 isolated from Streptomyces sp. SANK 62799, and A102395 from Amycolatopsis sp. SANK 60206 all share this putative SHMT within
the biosynthetic gene cluster. Previous research in our group has already shown
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the necessity of the putative SHMTs in the formation of the final compound due
to the abolishment of product when the SHMT-like gene is deleted from the
biosynthetic gene cluster. Therefore, we turned to heterologous expression of
the putative SHMTs from each of the above-mentioned compounds for in vitro
analysis of enzymatic activity and characterization of the enzymatic product.
Interestingly we were only able to get soluble protein from Streptomyces host.
Perhaps more interesting was the discovery of the true activity of these SHMT
homologues as L-Thr UA transaldolases. This is in contrast to our first
hypothesis that Gly or Ser was used as a glycyl unit donor.

After identification of (5S, 6S)-GlyU as the enzymatic product, we tested our next
hypothesis that the putative SHMTs could serve as an intermediate in the
formation of CarU, the core structure of the capuramycin-related compounds. As
expected, based on sequence similarity, Orf25 and CapH had identical activity to
LipK and Mra14. Furthermore, isotopically labeled precursors enabled us to
identify L-Thr incorporation into the final compound A-503083 and helped us to
verify the activity and necessity of the putative SHMTs in formation of the CarU
structure. This result suggest more interesting chemistry is yet to be discovered
during the conversion of GlyU to CarU during capuramycin biosynthesis.

Finally, identification of the enzymatic activity of the putative SHMTs and the role
they play in the biosynthesis of caprazamycin and capuramycin-related
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compounds led us to inquire into a potential alternative activity of the canonical
SHMT and LTA, GlyA and EcLTA respectively. Analysis of the results from the
enzymatic assays using the putative SHMT LipK, as well as EcGlyA and EcLTA,
revealed identical HPLC traces as well as the formation of acetaldehyde, the
secondary product. Preliminary results indicate that indeed both the EcGlyA and
the EcLTA do act in a mechanistic method mimicking that of the transaldolase
isolated from the caprazamycin and capuramycin-related compounds. Overall,
the heterologous expression, characterization, and in vivo analysis of the putative
SHMTs studied in this dissertation offers insight into novel chemistry utilized by
organisms to form novel, complex antibacterial compounds.

Copyright © Sandra Hummel Barnard 2013	
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Chapter Five
Final Thoughts
The continual search for methods enabling the formation of β-hydroxy-α-amino
acids continues throughout the scientific community. The requirement of βhydroxy-α-amino acids in formation of biologically active antibiotics make them
ideal scaffolds to build novel antibacterial compounds, however the ability to
synthesize enantiomerically pure products still remains challenging (60-63).

This dissertation has revealed the LipK family of L-threonine:uridine-5ʹ′-aldehyde
transaldolases as putative SHMTs that catalyze an L-Thr-dependent βsubstitution reaction by means of a sequential Cα-Cβ bond breaking and reformation (Fig. 4.1) to form the nonproteinogenic β-hydroxy-α-amino acid (5ʹ′S,
6ʹ′S)-GlyU intermediate. Differing in its preference for L-Thr as opposed to L-alloThr preferred by canonical LTAEs (4), LipK displays activity similar to that of 4fluorothreonine transaldolase (FTase). Despite sharing only 25% sequence
identity within the SHMT-like domain (Fig. 4.2), both LipK and FTase catalyze an
L-Thr-dependent

β-substitution reaction by means of a Cα-Cβ bond breaking and

creation (64, 65). With the Lys residue identified as key in the formation of an
external aldimine, and the C-C bond extension capability, LipK paves the way for
inquiry into the more canonical enzymes EcGlyA and EcLTA, also utilizing
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external aldimine formation and C-C bond extension, which we have tagged as
having potential L-Thr transaldolase activity.

Providing another distinct mechanism for C-C bond formation for sugars, LipK
differs from the more traditional aldolase and transketolase group of enzymes
which employ a carbonyl-group-containing substrate as the donor (66). Instead,
LipK uses an amino acid as the donor and yields a β-sugar substituted α-amino
acid. Not only could the ability of these novel enzymes for C-C bond formation
provide another means of preparing previously un-synthesizable sugars and
unusual amino acids, but the amalgamating ability utilizing amino acids into
nucleoside antibiotics may provide another means for identifying complex, novel
antibacterial compounds.
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Figure 4.1 Putative chemical mechanism of L-Thr:UA transaldolases. The
enzyme in the holo-form (I) binds L-Thr to generate the external aldimine (II) and
UA to form a ternary complex. An enzyme base deprotonates the β-hydroxyl to
initiate the retro-aldol-type reaction, a step that is likely rate limiting considering
no additional UV-active intermediates such as species III are detected throughout
the course of the reaction. The formed acetaldehyde subsequently diffuses from
the active site allowing UA to position in the same relative orientation. Attack of
III on the si face in the aldol-type reaction with UA generates intermediate IV
prior to release of the two products and regeneration of the holo-enzyme I. In the
absence of UA, a retro-aldol reaction can occur to putatively generate
intermediate III, which was not detected by UV/Vis spectroscopy.
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A

B

▼	
  

Figure 4.2. Enzymes catalyzing an L-Thr-dependent β-substitution. (A)
Reaction catalyzed by 4-fluorothreonine transaldolase (FTase). The activity was
initially discovered based on isolation of the native enzyme from the 4fluorothreonine producing-strain Streptomyces cattleya. (B) Sequence alignment
of FTase and LipK. FTase, the sequence of which was identified using reverse
genetics, consists of two putative domains: an N-terminal SHMT-like domain and
a C-terminal phosphate-binding domain of bacterial sugar epimerases and
aldolases. One such epimerase homologue, AraD, catalyzes a reversible retroaldol reaction with ribulose-1-phosphate. Due to limiting expression levels,
recombinant FTase that was partially purified from Streptomyces lividans was
used solely to reconstitute the biosynthetic pathway of 4-fluorothreonine, thus the
exact function of each domain remains undefined. LipK has a relatively low
sequence identity of 25% (36% similarity) to the N-terminal domain of FTase, but
the results with LipK suggest the transaldolase activity is likely harbored within
this domain. ▼, conserved Lys required for formation of the internal aldimine with
pyridoxal-5'-phosphate.
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